At present three potential pharmacological strategies based on TRAIL signalling targeting have been designed: (i) use of recombinant human TRAIL; (ii) administration of activating humanized antibodies directed against TRAIL receptors TRAIL-R1 or TRAIL-R2; (iii) adenoviral delivery of the TRAIL coding sequence into tumor cells (Ad5-TRAIL). Here, TNFSF10 is linked to neoplasm.